Adial Pharmaceuticals Appoints Chief Scientist to Lead AT177 Program
Adial Pharmaceuticals appointed David Rubenstein, M.D., Ph.D., as chief scientist to lead AT177 through IND-enabling work toward first-in-human trials expected in 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.